COMT inhibition and safety.
Martignoni
E
E
Parkinson's Disease and Movement Disorders Center, IRCCS C. Mondino Institute of Neurology, Pavia, Italy. emilia.martignoni@libero.it
Blandini
F
F
Pacchetti
C
C
Nappi
G
G
D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001577:Benzophenones / Q000009:adverse effects* / Q000627:therapeutic use*; D065098:Catechol O-Methyltransferase Inhibitors; D002396:Catechols / Q000009:adverse effects* / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D004791:Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D009570:Nitriles; D009596:Nitrophenols; D012449:Safety; D000077867:Tolcapone
D000978:Antiparkinson Agents; D001577:Benzophenones; D065098:Catechol O-Methyltransferase Inhibitors; D002396:Catechols; D004791:Enzyme Inhibitors; D009570:Nitriles; D009596:Nitrophenols; C071192:entacapone; D000077867:Tolcapone